AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12920408 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/d
Number of subjects: 39
Study 12920408 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 600 mg/d
Number of subjects: 39
Study 12920408 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (4-week trial)
Number of subjects: 39
Study 12920408 — intervention group
Group type: COMPARATOR
Intervention: Other antipsychotics and low doses of antiparkinsonians
Number of subjects: 39
Study 12920408 — intervention group
Group type: EXPERIMENTAL
Intervention: Norclozapine
Number of subjects: 39
Study 12920408 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 39
Study 10914361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate adaptive atrial pacing therapy
Number of subjects: 97
Study 10914361 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing postablation
Number of subjects: 97
Study 10914361 — intervention group
Group type: COMPARATOR
Intervention: VDD pacing postablation
Number of subjects: 97
Study 10914361 — intervention group
Group type: COMPARATOR
Intervention: No atrial pacing therapy
Number of subjects: 97
Study 9006183 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle teaching
Number of subjects: 24
Study 9006183 — intervention group
Group type: COMPARATOR
Intervention: Behaviour modification
Number of subjects: 24
Study 1319601 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked marijuana
Number of subjects: 21
Study 1319601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 21
Study 1319601 — intervention group
Group type: COMPARATOR
Intervention: Smoked marijuana and Oral THC
Number of subjects: 21
Study 6478738 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg + Methadone 100% of maintenance dose
Number of subjects: 5
Study 6478738 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 40 mg + Methadone 150% of maintenance dose
Number of subjects: 5
Study 6478738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6478738 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 100% of maintenance dose
Number of subjects: 5
Study 6478738 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 150% of maintenance dose
Number of subjects: 5
Study 6478738 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 200% of maintenance dose
Number of subjects: 5
Study 30734266 — intervention group
Group type: EXPERIMENTAL
Intervention: mirikizumab 30 mg
Number of subjects: 204
Study 30734266 — intervention group
Group type: EXPERIMENTAL
Intervention: mirikizumab 100 mg
Number of subjects: 204
Study 30734266 — intervention group
Group type: EXPERIMENTAL
Intervention: mirikizumab 300 mg
Number of subjects: 204
Study 30734266 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 204
Study 30397355 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month regimens
Number of subjects: 3405
Study 30397355 — intervention group
Group type: EXPERIMENTAL
Intervention: High smear grades and cavitation
Number of subjects: 3405
Study 30397355 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence of ≤90%
Number of subjects: 3405
Study 30397355 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline smear grade of 3+
Number of subjects: 3405
Study 30397355 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seropositivity
Number of subjects: 3405
Study 25786826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet (A) group
Number of subjects: 84
Study 25786826 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet (B) group
Number of subjects: 84
Study 24521993 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (1400 mg)
Number of subjects: 127
Study 24521993 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2)
Number of subjects: 127
Study 21720426 — intervention group
Group type: EXPERIMENTAL
Intervention: Full subsidy (8 weight loss counseling visits and 2 meals per day)
Number of subjects: 50
Study 21720426 — intervention group
Group type: COMPARATOR
Intervention: Partial subsidy (8 weight loss counseling visits and 1 meal per day)
Number of subjects: 50
Study 21720426 — intervention group
Group type: EXPERIMENTAL
Intervention: Full subsidy
Number of subjects: 50
Study 21720426 — intervention group
Group type: COMPARATOR
Intervention: Partial subsidy
Number of subjects: 50
Study 20581167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy with bronchoalveolar lavage (FO-BAL) plus noninvasive tests (n = 113)
Number of subjects: 219
Study 20581167 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive tests only (n = 106)
Number of subjects: 219
Study 17869596 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infusion (16.25mg/h for 24h)
Number of subjects: 46
Study 17869596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15812806 — intervention group
Group type: COMPARATOR
Intervention: Normal renal arteries
Number of subjects: 35
Study 15812806 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery fibromuscular dysplasia (FMD)
Number of subjects: 35
Study 11448018 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 mg/day etidronate
Number of subjects: 80
Study 11448018 — intervention group
Group type: EXPERIMENTAL
Intervention: 133 mg/day etidronate
Number of subjects: 80
Study 11448018 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day etidronate
Number of subjects: 80
Study 11448018 — intervention group
Group type: COMPARATOR
Intervention: No etidronate (Control Group A)
Number of subjects: 80
Study 9746768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/methotrexate
Number of subjects: 0
Study 9746768 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine/methotrexate
Number of subjects: 0
Study 8040990 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc MIBI injection during stress testing
Number of subjects: 16
Study 3181147 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 180
Study 3181147 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 180
Study 3181147 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 180
Study 31112070 — intervention group
Group type: EXPERIMENTAL
Intervention: Static images of different lifting techniques
Number of subjects: 18
Study 28779921 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 83
Study 28779921 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 83
Study 24828371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematogram model for predicting future MetS in elderly men
Number of subjects: 4539
Study 24828371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematogram model for predicting future MetS in elderly women
Number of subjects: 4539
Study 23383690 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute resistance training (RT) session
Number of subjects: 24
Study 21912466 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 0
Study 21912466 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomicroscopy
Number of subjects: 0
Study 21912466 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic procedure (four biopsies every 10 cm)
Number of subjects: 0
Study 19506112 — intervention group
Group type: EXPERIMENTAL
Intervention: DITPA
Number of subjects: 86
Study 19506112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17709433 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined olive oil (50 g/m² body surface area)
Number of subjects: 14
Study 17709433 — intervention group
Group type: EXPERIMENTAL
Intervention: High-palmitic sunflower oil (50 g/m² body surface area)
Number of subjects: 14
Study 17709433 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter (50 g/m² body surface area)
Number of subjects: 14
Study 17709433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of vegetable and fish oils (50 g/m² body surface area)
Number of subjects: 14
Study 17709433 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial TRL at 3 h
Number of subjects: 14
Study 17709433 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial TRL at 5 h
Number of subjects: 14
Study 17709433 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial TRL
Number of subjects: 14
Study 15018874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber ICD (DDED)
Number of subjects: 343
Study 15018874 — intervention group
Group type: COMPARATOR
Intervention: Single chamber ICD (SC)
Number of subjects: 343
Study 15018874 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite primary endpoint includes: all-cause mortality, invasive intervention, hospitalization due to cardiovascular cause, inappropriate shocks, sustained symptomatic atrial tachyarrhythmias requiring urgent termination or lasting more than 48h.
Number of subjects: 343
Study 15018874 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints include individual components of CSAE, cardiovascular status, quality of life, and analysis of atrial and ventricular arrhythmias.
Number of subjects: 343
Study 11485526 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GBP)
Number of subjects: 70
Study 11485526 — intervention group
Group type: COMPARATOR
Intervention: Open gastric bypass (GBP)
Number of subjects: 70
Study 9724277 — intervention group
Group type: EXPERIMENTAL
Intervention: hNPY 14.3 pmol . kg‐1 . min‐1
Number of subjects: 12
Study 9724277 — intervention group
Group type: EXPERIMENTAL
Intervention: hNPY 1.4 pmol . kg‐1 . min‐1
Number of subjects: 12
Study 9724277 — intervention group
Group type: COMPARATOR
Intervention: Control (no hNPY)
Number of subjects: 12
Study 7805426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 76
Study 7805426 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid (500 mg three times daily)
Number of subjects: 76
Study 3199275 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose/glycine/glycylglycine-based ORS
Number of subjects: 62
Study 3199275 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO/ORS
Number of subjects: 62
Study 30333054 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 940
Study 30333054 — intervention group
Group type: COMPARATOR
Intervention: Conversion to IUI
Number of subjects: 940
Study 28375706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes without metformin treatment
Number of subjects: 8381
Study 28375706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes with metformin treatment
Number of subjects: 8381
Study 28375706 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 8381
Study 28375706 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 8381
Study 25442801 — intervention group
Group type: EXPERIMENTAL
Intervention: CT density distribution kurtosis (iKurtosis)
Number of subjects: 26
Study 25442801 — intervention group
Group type: EXPERIMENTAL
Intervention: CT density distribution skewness (iSkewness)
Number of subjects: 26
Study 25442801 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-iKurtosis
Number of subjects: 26
Study 25442801 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-iSkewness
Number of subjects: 26
Study 25442801 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologic scores (RS1 and RS2)
Number of subjects: 26
Study 23147718 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage group (full screening plus option of personalized phone triage)
Number of subjects: 549
Study 23147718 — intervention group
Group type: COMPARATOR
Intervention: Minimal screening group (Distress Thermometer plus usual care)
Number of subjects: 549
Study 23147718 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage group
Number of subjects: 549
Study 23147718 — intervention group
Group type: EXPERIMENTAL
Intervention: Full screening group (Distress Thermometer, CPC, Pain Thermometer, Fatigue Thermometer, Psychological Screen for Cancer Part C)
Number of subjects: 549
Study 23147718 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 549
Study 23147718 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals
Number of subjects: 549
Study 21896815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive latrine promotion
Number of subjects: 320
Study 21896815 — intervention group
Group type: COMPARATOR
Intervention: Control (no latrine promotion)
Number of subjects: 320
Study 21896815 — intervention group
Group type: COMPARATOR
Intervention: Latrine promotion vs Control
Number of subjects: 320
Study 19846406 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 39
Study 19846406 — intervention group
Group type: COMPARATOR
Intervention: LMA-Unique (LMA-U)
Number of subjects: 39
Study 16924356 — intervention group
Group type: EXPERIMENTAL
Intervention: Clingfilm covering during phototherapy
Number of subjects: 106
Study 16924356 — intervention group
Group type: COMPARATOR
Intervention: No clingfilm covering during phototherapy
Number of subjects: 106
Study 15153664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg once daily for 12 weeks
Number of subjects: 6
Study 11286302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimetazidine
Number of subjects: 0
Study 11286302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 0
Study 8900987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated G-suit (50 mm Hg)
Number of subjects: 1
Study 8900987 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-inflated G-suit
Number of subjects: 1
Study 8900987 — intervention group
Group type: COMPARATOR
Intervention: Without G-suit
Number of subjects: 1
Study 8900987 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic subjects)
Number of subjects: 1
Study 2108511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 7
Study 2108511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 85871 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine isotope scanning
Number of subjects: 46
Study 85871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 46
Study 31489410 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl with ultrasound devices
Number of subjects: 0
Study 31489410 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 0
Study 31489410 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 0
Study 28650087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health educational strategy (OHES) and Atraumatic Restorative Treatment (ART) restoration
Number of subjects: 72
Study 28650087 — intervention group
Group type: COMPARATOR
Intervention: Oral health educational strategy (OHES)
Number of subjects: 72
Study 25866155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of Lentinula edodes (shiitake) mushrooms daily
Number of subjects: 52
Study 25866155 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of Lentinula edodes (shiitake) mushrooms daily
Number of subjects: 52
Study 25866155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinula edodes (shiitake) mushrooms consumption
Number of subjects: 52
Study 24525232 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (methotrexate, vinblastine, doxorubicin, cisplatin)
Number of subjects: 0
Study 22774398 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal balneotherapy with ozonized water
Number of subjects: 30
Study 22774398 — intervention group
Group type: COMPARATOR
Intervention: Non-mineral water bath (control)
Number of subjects: 30
Study 20573380 — intervention group
Group type: EXPERIMENTAL
Intervention: TUNEL assay
Number of subjects: 194
Study 18052593 — intervention group
Group type: EXPERIMENTAL
Intervention: eEVAR (n=18)
Number of subjects: 49
Study 18052593 — intervention group
Group type: COMPARATOR
Intervention: Open repair (n=31)
Number of subjects: 49
Study 18052593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed prospective group
Number of subjects: 49
Study 18052593 — intervention group
Group type: COMPARATOR
Intervention: Historical open repair group
Number of subjects: 49
Study 16287407 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimistic message weight loss program
Number of subjects: 349
Study 16287407 — intervention group
Group type: COMPARATOR
Intervention: Balanced message weight loss program
Number of subjects: 349
Study 12163798 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidemic septic shock
Number of subjects: 10
Study 12163798 — intervention group
Group type: COMPARATOR
Intervention: Bacteremic septic shock
Number of subjects: 10
Study 10394686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine 3 mg + Piracetam 1.6 g every 12 hours for 90 days
Number of subjects: 50
Study 10394686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine 1.5 mg + Piracetam 0.8 g every 8 hours for 90 days
Number of subjects: 50
Study 10394686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10394686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine-Piracetam (D-P)
Number of subjects: 50
Study 10394686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine 1.5 mg + Piracetam 0.8 g every 8 hours
Number of subjects: 50
Study 8785138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-atracurium 0.18 mg kg‐1 h‐1 (group 1, n = 6)
Number of subjects: 12
Study 8785138 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1 h‐1 (group 2, n = 6)
Number of subjects: 12
Study 8785138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-atracurium
Number of subjects: 12
Study 8785138 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 12
Study 1645087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tar, low nicotine cigarettes
Number of subjects: 0
Study 1645087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tar, middle nicotine cigarettes
Number of subjects: 0
Study 1645087 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tar, middle nicotine cigarettes
Number of subjects: 0
Study 6149589 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked marijuana (1 g cigarette containing 1.83% delta 9-THC)
Number of subjects: 24
Study 6149589 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta 9-THC (17.5 mg)
Number of subjects: 24
Study 6149589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg orally)
Number of subjects: 24
Study 6149589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31498030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1077
Study 31498030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1077
Study 31498030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 1077
Study 29530271 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine (LT4) treatment; specific dosage and duration not mentioned.
Number of subjects: 150
Study 27445468 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 µg
Number of subjects: 0
Study 27445468 — intervention group
Group type: COMPARATOR
Intervention: UMEC 62.5 µg
Number of subjects: 0
Study 27445468 — intervention group
Group type: COMPARATOR
Intervention: VI 25 µg
Number of subjects: 0
Study 27445468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27445468 — intervention group
Group type: COMPARATOR
Intervention: TIO 18 µg
Number of subjects: 0
Study 24478226 — intervention group
Group type: EXPERIMENTAL
Intervention: Axxess stent
Number of subjects: 76
Study 24478226 — intervention group
Group type: COMPARATOR
Intervention: Distal sirolimus‐eluting stents
Number of subjects: 76
Study 22627912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diets (65% or 55% carbohydrate)
Number of subjects: 811
Study 22627912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diets (45% or 35% carbohydrate)
Number of subjects: 811
Study 22627912 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured REE at 6 months
Number of subjects: 811
Study 22627912 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured REE at 24 months
Number of subjects: 811
Study 22627912 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 811
Study 19117977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free, head-controlled pointer
Number of subjects: 20
Study 19117977 — intervention group
Group type: COMPARATOR
Intervention: Verbal guidance only
Number of subjects: 20
Study 17253908 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 57
Study 17253908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 15996945 — intervention group
Group type: EXPERIMENTAL
Intervention: cladribine + prednisone
Number of subjects: 0
Study 15996945 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil + prednisone
Number of subjects: 0
Study 11993621 — intervention group
Group type: EXPERIMENTAL
Intervention: CREATINE (5 g of Cr, 4 times per day for 6 days)
Number of subjects: 12
Study 11993621 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO (same dosage of a glucose polymer)
Number of subjects: 12
Study 9513799 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.6 mg)
Number of subjects: 6
Study 9513799 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (16 mg)
Number of subjects: 6
Study 9513799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (30 mg)
Number of subjects: 6
Study 9513799 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 6
Study 7710024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal catheter with foam collar
Number of subjects: 11
Study 7710024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson mask
Number of subjects: 11
Study 7710024 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannulae
Number of subjects: 11
Study 2153355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, 4 times daily for 4 months)
Number of subjects: 25
Study 2153355 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 micrograms, 4 times daily for 4 months)
Number of subjects: 25